top of page

No-Exam Term Life Insurance After Basal Cell or Squamous Cell Skin Cancer

Written by: Jeff Schmidt | Licensed Insurance Broker | CarePro Insurance Content reviewed for accuracy. Not legal, tax, or financial advice.

Basal cell and squamous cell skin cancers are often underwritten differently than melanoma. Underwriters typically focus on the type, treatment, margins, and follow-up history.

  • Instant online pricing

  • No phone calls required

  • No pressure from agents

Basal vs Squamous: The Details Matter

Which skin cancer type you had (and why it matters)

Treatment details: excision, Mohs, margins, recurrence

How time since treatment can affect options

Skin cancer history can sound scary, but underwriting usually starts with one simple clarification: what type was it? Basal cell and squamous cell are typically treated differently than melanoma. Basal cell carcinoma is the most common skin cancer and almost never spreads to other organs - that's why a single, fully treated BCC is typically viewed as low-risk, particularly when it was removed with clear margins and has not recurred. Squamous cell carcinoma is the second most common type, still usually curable when caught early, but it carries a slightly higher rate of regional spread than BCC, so underwriters look more carefully at stage, location on the body, and whether treatment was complete and produced clean margins. High-risk locations for squamous cell carcinoma - such as the ear, lip, or nose - are flagged more carefully than low-risk locations like the trunk, because anatomical location is correlated with recurrence and regional spread risk.

For no-exam programs, carriers may still ask follow-up questions about treatment and timing. They often want to know when it was treated, whether margins were clear, and whether there's been any recurrence. 'Clear margins' means the pathology report confirmed a clean border of healthy tissue surrounding the removed cancer - indicating the tumor was fully excised - and this is one of the most important documented outcomes underwriters look for. Mohs surgery, a technique where tissue layers are removed and examined under a microscope in real time during the procedure, almost always produces clear margins and is viewed favorably in underwriting because it directly supports the completeness of treatment.

If it was a single, fully treated basal cell carcinoma years ago, underwriting is often more straightforward. More recent treatment, repeated occurrences, or higher-risk findings can trigger a deeper review. Melanoma is staged from I through IV, and early-stage I melanoma treated several years ago is underwritten very differently than stage III or IV disease or a recent diagnosis. Clark level - which describes how deeply the melanoma has penetrated through the layers of skin - is another specific data point that underwriting may ask about or locate in medical records for melanoma cases, because depth of invasion is directly tied to recurrence and spread risk. Melanoma stage is the primary driver of how long a carrier may want to see post-treatment before issuing coverage, with stage I cases often qualifying sooner than stage II cases, and higher stages potentially requiring significantly longer clean periods or triggering exclusions.

When you compare quotes, make sure each quote is based on the same type and timing. 'Skin cancer' is too broad - the details can shift the outcome. A quote input that says 'skin cancer, treated, no recurrence' can mean basal cell removed three years ago or stage II melanoma removed last year - and those represent fundamentally different underwriting scenarios that will produce very different rate classes and outcomes. Supplying the specific type, the treatment date, the surgical method, and the margin status when you request quotes helps ensure the estimate reflects your actual history rather than a best-case assumption. If you had radiation as part of your treatment in addition to surgery, noting that detail upfront helps underwriting understand the full scope of what was done and reduces the chance of follow-up questions that slow the review.

Have your diagnosis type, treatment date, and follow-up schedule ready. It's the quickest way to keep underwriting from stalling on missing information. If dermatology follow-up appointments are part of your ongoing care - as they often are after any skin cancer diagnosis - having the date of your most recent visit and the outcome helps document active monitoring. Carriers generally view regular dermatology follow-up as a positive indicator that any recurrence would be caught early and managed promptly, which speaks to the ongoing risk picture rather than just the original treatment. Recurrence-free intervals measured in years - not months - are generally what shift a skin cancer case from 'requires careful review' to 'straightforward,' and the difference between two years and five years of clean follow-up can be a full rate class.

For the full instant/no-exam term life overview, see: https://www.careproinsurance.com/instant-term-life-insurance

This page is educational; seek professional guidance for legal, tax, or medical matters. Quotes are estimates and final decisions depend on underwriting and carrier guidelines.

Frequently Asked Questions

Can I get no-exam term life insurance after basal cell carcinoma?

Sometimes. Many carriers consider applicants after basal cell carcinoma, especially when it was fully treated and there's been no recurrence. Guidelines vary by carrier and timing.

Is squamous cell carcinoma treated differently than basal cell?

Often, yes. Underwriters may view squamous cell as higher risk than basal cell, depending on the case. Treatment details and recurrence history are important.

What skin cancer information do carriers usually ask for?

Common questions include type (basal vs squamous vs melanoma), dates, treatment method (excision/Mohs), whether margins were clear, and whether there's been recurrence.

How long after treatment should I wait to apply?

There isn't a single rule. Some carriers are comfortable soon after successful treatment; others prefer a longer window. Timing depends on type and severity.

Does melanoma change things?

Yes. Melanoma is generally underwritten more strictly and often involves longer waiting periods or more requirements. Basal and squamous cases are typically evaluated differently.

What does 'clear margins' mean, and how does it affect the underwriting outcome?

Clear margins means the pathology report confirmed that the removed tissue had a border of healthy, cancer-free cells surrounding it - indicating the tumor was fully excised. Underwriting treats clear margins as a strong positive indicator that treatment was complete. If margins were not clear and a second procedure was required, that detail will likely come up as a follow-up question, along with the outcome of any additional treatment.

Is squamous cell carcinoma treated the same as basal cell carcinoma by underwriters?

Not always - squamous cell carcinoma has a modestly higher risk of regional spread than basal cell, so underwriters tend to ask more questions about stage, location, and how completely it was treated. A small, low-risk SCC removed with clear margins several years ago is generally viewed favorably, while SCC on higher-risk locations or with incomplete margins may receive more scrutiny. The specifics matter more than the label.

If I've had multiple basal cell removals over the years, does that change the picture versus a single case?

Multiple BCC removals don't automatically disqualify an application, but recurring skin cancer does introduce additional questions - primarily about monitoring frequency and whether any removal involved more complex treatment. Carriers want to see that each occurrence was treated promptly and fully. If dermatology follow-up is regular and each treated BCC had clear margins, many carriers still treat the case as manageable, though the rate class may reflect the recurrence pattern.

Get Covered With The Right Plan

Make the skin cancer distinctions clear (basal vs squamous vs melanoma), and focus on treatment, margins, and follow-up timelines.

Check your term options

bottom of page